leisure time -WSS

leisure time

author：explore 2025-09-06 03:40:05 - browse：4939

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Target recalls 2.2 million additional candles due to laceration, burn hazards

WSS

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Congress must give Medicare recipients genetic counseling access

Eye stem cell transplant could help restore vision in injured people

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

The pain doctors face in trying to build their families

The history of OxyContin, told through Purdue Pharma documents

focus

leisure time

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eye stem cell transplant could help restore vision in injured people

Dobbs anniversary: the lost opportunity of abortion as health care

An interview with Robert F. Kennedy Jr. on vaccines

BioMarin wins approval for gene therapy to treat hemophilia A

Listen: Racing for gene therapy & a pioneering approval

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Novo acquires Inversago for up to $1 billion

Affirmative action in medical school literally saved lives

Hilary expected to bring catastrophic, life

entertainment

Timeline: Special counsel's investigation into Trump's handling of classified documents

Where are patients getting their prescriptions for GLP

Target recalls 2.2 million additional candles due to laceration, burn hazards

Congress must give Medicare recipients genetic counseling access

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Faced with fears of OxyContin misuse, sales reps touted its safety

hotspot

leisure time

leisure time

focus